Dysregulation of long non-coding RNA ZFAS1 in children with obesity and its predictive value for metabolic syndrome
Abstract
Introduction: The purpose of this study was to analyse the correlation between zinc finger antisense 1 (ZFAS1) and obesity and the diagnostic value of obesity complicated with metabolic syndrome (obesity-MS).
Material and methods: Serum levels of ZFAS1 were measured by quantitative real-time polymerase chain reaction (qRT-PCR) in healthy children, children with simple obesity, and children with obesity-MS. The diagnostic accuracy of ZFAS1 was evaluated using the receiver operator characteristic (ROC) curve. Pearson’s method was used to study the correlation between ZFAS1 and other indicators. Logistic regression was used to analyse the significance of ZFAS1 in the progression of obesity to obesity-MS. StarBase V2.0 was used to predict the target gene of ZFAS1 (miR-193a-3p). Bioinformatics methods were used to identify the molecular functions and possible enrichment signalling pathways of downstream target genes of miR-193a-3p.
Results: The expression of ZFAS1 in patients with obesity and obesity-MS showed a gradual upward trend, while the expression of miR-193a-3p was the opposite. ZFAS1 could identify obesity-MS children from children with obesity (area under the curve [AUC] = 0.880). ZFAS1 was significantly correlated with body mass index (BMI), waist circumference (WC), systolic blood pressure (SBP), and other indicators, while ZFAS1 was an independent influencing factor for the development of obesity into obesity-MS. Furthermore, a total of 104 downstream target genes of miR-193a-3p were identified, which participated in many biological processes such as protein phosphatase regulation, activation of transcription factor activity, and enrichment in MAPK signalling pathway.
Conclusion: ZFAS1 is dysregulated in obesity and obesity-MS. Abnormal expression of ZFAS1 has high diagnostic value for obesity-MS, and it has the potential to become a clinical diagnostic biomarker for obesity-MS.
Keywords: ZFAS1obesitymetabolic syndromemiR-193a-3p
References
- Panichsillaphakit E, Chongpison Y, Saengpanit P, et al. Children's Eating Behavior Questionnaire Correlated with Body Compositions of Thai Children and Adolescents with Obesity: A Pilot Study. J Nutr Metab. 2021; 2021: 6496134.
- Jones J, Wolfenden L, Wyse R, et al. A randomised controlled trial of an intervention to facilitate the implementation of healthy eating and physical activity policies and practices in childcare services. BMJ Open. 2014; 4(4): e005312.
- Mayoral LPC, Andrade GM, Mayoral EPC, et al. Obesity subtypes, related biomarkers & heterogeneity. Indian J Med Res. 2020; 151(1): 11–21.
- Lanigan J, Barber S, Singhal A. Prevention of obesity in preschool children. Proc Nutr Soc. 2010; 69(2): 204–210.
- Gustafson B, Hedjazifar S, Gogg S, et al. Insulin resistance and impaired adipogenesis. Trends Endocrinol Metab. 2015; 26(4): 193–200.
- Aggoun Y. Obesity, metabolic syndrome, and cardiovascular disease. Pediatr Res. 2007; 61(6): 653–659.
- Wang Y, Wang M, Chen J, et al. The gut microbiota reprograms intestinal lipid metabolism through long noncoding RNA . Science. 2023; 381(6660): 851–857.
- Jin SS, Lin CJ, Lin XF, et al. Silencing lncRNA NEAT1 reduces nonalcoholic fatty liver fat deposition by regulating the miR-139-5p/c-Jun/SREBP-1c pathway. Ann Hepatol. 2022; 27(2): 100584.
- Cao SQ, Zheng H, Sun BC, et al. Long non-coding RNA highly up-regulated in liver cancer promotes exosome secretion. World J Gastroenterol. 2019; 25(35): 5283–5299.
- Zhang J, Quan LN, Meng Q, et al. miR-548e Sponged by ZFAS1 Regulates Metastasis and Cisplatin Resistance of OC by Targeting CXCR4 and let-7a/BCL-XL/S Signaling Axis. Mol Ther Nucleic Acids. 2020; 20: 621–638.
- Fan S, Fan C, Liu N, et al. Downregulation of the long non-coding RNA ZFAS1 is associated with cell proliferation, migration and invasion in breast cancer. Mol Med Rep. 2018; 17(5): 6405–6412.
- Liu Lu, Sun S, Li X. LncRNA ZFAS1 ameliorates injury led by non-alcoholic fatty liver disease via suppressing lipid peroxidation and inflammation. Clin Res Hepatol Gastroenterol. 2023; 47(1): 102067.
- Tang X, Yin R, Shi H, et al. LncRNA ZFAS1 confers inflammatory responses and reduces cholesterol efflux in atherosclerosis through regulating miR-654-3p-ADAM10/RAB22A axis. Int J Cardiol. 2020; 315: 72–80.
- Mansoori Y, Tabei MB, Askari A, et al. A link between expression level of long-non-coding RNA in breast tissue of healthy women and obesity. Int J Biol Markers. 2018; 33(4): 500–506.
- Núñez-Enríquez JC, Gil-Hernández AE, Jiménez-Hernández E, et al. Overweight and obesity as predictors of early mortality in Mexican children with acute lymphoblastic leukemia: a multicenter cohort study. BMC Cancer. 2019; 19(1): 708.
- Wu W, Zhang H, Xu X, et al. Intrahepatic Fat Content and Markers of Hepatic Fibrosis in Obese Children. Int J Endocrinol. 2016; 2016: 4890974.
- Zhao Di, Wang X, Beeraka NM, et al. High Body Mass Index Was Associated With Human Epidermal Growth Factor Receptor 2-Positivity, Histological Grade and Disease Progression Differently by Age. World J Oncol. 2023; 14(1): 75–83.
- Wang M, Huang Y, Xin M, et al. The impact of microbially modified metabolites associated with obesity and bariatric surgery on antitumor immunity. Front Immunol. 2023; 14: 1156471.
- Neeland IJ, Ross R, Després JP, et al. International Atherosclerosis Society, International Chair on Cardiometabolic Risk Working Group on Visceral Obesity. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019; 7(9): 715–725.
- Wang H, Chen Y, Liu Y, et al. The lncRNA ZFAS1 regulates lipogenesis in colorectal cancer by binding polyadenylate-binding protein 2 to stabilize SREBP1 mRNA. Mol Ther Nucleic Acids. 2022; 27: 363–374.
- Wang L, Ruan Yi, Wu X, et al. lncRNA ZFAS1 Promotes HMGCR mRNA Stabilization via Binding U2AF2 to Modulate Pancreatic Carcinoma Lipometabolism. J Immunol Res. 2022; 2022: 4163198.
- Yin Q, He M, Huang Li, et al. lncRNA ZFAS1 promotes ox-LDL induced EndMT through miR-150-5p/Notch3 signaling axis. Microvasc Res. 2021; 134: 104118.
- Liu J, Wang H, Zeng D, et al. The novel importance of miR-143 in obesity regulation. Int J Obes (Lond). 2023; 47(2): 100–108.
- Sun H, Seok S, Jung H, et al. Obesity-induced miR-802 directly targets AMPK and promotes nonalcoholic steatohepatitis in mice. Mol Metab. 2022; 66: 101603.
- Yin B, Umar T, Ma X, et al. MiR-193a-3p targets LGR4 to promote the inflammatory response in endometritis. Int Immunopharmacol. 2021; 98: 107718.
- Ma T, Li H, Yang W, et al. Over-expression of miR-193a-3p regulates the apoptosis of colorectal cancer cells by targeting PAK3. Am J Transl Res. 2022; 14(2): 1361–1375.
- Meerson A, Traurig M, Ossowski V, et al. Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-α. Diabetologia. 2013; 56(9): 1971–1979.
- Cui X, Wang Z, Liu L, et al. The Long Non-coding RNA ZFAS1 Sponges miR-193a-3p to Modulate Hepatoblastoma Growth by Targeting RALY via HGF/c-Met Pathway. Front Cell Dev Biol. 2019; 7: 271.
- Qu L, Tian Y, Hong D, et al. Mig-6 Inhibits Autophagy in HCC Cell Lines by Modulating miR-193a-3p. Int J Med Sci. 2022; 19(2): 338–351.
- Wu T, Liu Q, Li Y, et al. Feeding-induced hepatokine, Manf, ameliorates diet-induced obesity by promoting adipose browning via p38 MAPK pathway. J Exp Med. 2021; 218(6).
- Smekal A, Vaclavik J. Adipokines and cardiovascular disease: A comprehensive review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017; 161(1): 31–40.
- Binay Ç, Paketçi C, Güzel S, et al. Serum Irisin and Oxytocin Levels as Predictors of Metabolic Parameters in Obese Children. J Clin Res Pediatr Endocrinol. 2017; 9(2): 124–131.
- Castan-Laurell I, Dray C, Valet P. The therapeutic potentials of apelin in obesity-associated diseases. Mol Cell Endocrinol. 2021; 529: 111278.
- Blevins JE, Thompson BW, Anekonda VT, et al. Chronic CNS oxytocin signaling preferentially induces fat loss in high-fat diet-fed rats by enhancing satiety responses and increasing lipid utilization. Am J Physiol Regul Integr Comp Physiol. 2016; 310(7): R640–R658.
